Microbial Capabilities

Backed by over 30 years of scientific expertise and a robust global network spanning three continents, AGC Biologics delivers comprehensive microbial CDMO services designed to support biopharmaceutical developers at every stage.

Our microbial development and manufacturing capabilities are available at our facilities in Seattle (USA), Copenhagen (Denmark), Heidelberg (Germany), and Chiba (Japan), providing clients with flexible, regionally aligned support across the globe.

We offer end-to-end microbial services, including cell line development, process development, scale-up, and both clinical and commercial GMP manufacturing. Our teams bring deep technical experience across a wide range of microbial expression systems, including E. coli, Pichia pastoris (with or without methanol induction), Pseudomonas fluorescens (PFEnex system), Bacillus (non-sporulating strains), Lactobacillus casei, and other microbial hosts.

With robust GMP-compliant quality systems and a broad range of regulatory qualifications, we are equipped to meet manufacturing demands at any development phase. Our microbial production platforms include both stainless steel and single-use bioreactors, offering flexible batch sizes with capacities up to 3,000 liters.

Whether you're advancing a novel biologic or scaling a commercial product, AGC Biologics provides the expertise and infrastructure to help bring your microbial-based therapy to life.